Serum Lipids, Apolipoproteins, and Mortality among Coronary Artery Disease Patients
Table 3
HRs for all-cause and cardiovascular mortality according to different levels of apoA-I, apoB, and apoB/apoA-I.
Variable
Number of deaths
Person-years
Hazard ratios (95% confidence intervals)
All-cause mortality
CVD mortality
Total
CVD
Model 1a
Model 2b
Model 3c
Model 1a
Model 2b
Model 3c
ApoA-I
Quartile 1
51
41
1255
1.00
1.00
1.00
1.00
1.00
1.00
Quartile 2
34
25
1486
0.57 (0.37–0.88)
0.60 (0.38–0.94)
0.59 (0.38–0.92)
0.53 (0.32–0.88)
0.55 (0.33–0.93)
0.55 (0.33–0.91)
Quartile 3
26
19
1603
0.43 (0.26–0.69)
0.43 (0.26–0.71)
0.43 (0.26–0.70)
0.39 (0.23–0.69)
0.40 (0.23–0.70)
0.39 (0.22–0.70)
Quartile 4
36
28
1653
0.52 (0.34–0.81)
0.54 (0.34–0.86)
0.56 (0.35–0.88)
0.52 (0.31–0.85)
0.55 (0.33–0.93)
0.57 (0.34–0.95)
for trend
0.002
0.004
0.004
0.003
0.008
0.007
ApoB (mg/dL)
<90
102
77
4301
1.00
1.00
1.00
1.00
1.00
1.00
90–109
30
23
1104
1.33 (0.88–2.00)
1.35 (0.88–2.06)
1.35 (0.89–2.07)
1.36 (0.85–2.17)
1.38 (0.85–2.24)
1.39 (0.86–2.26)
≥110
15
13
593
1.74 (1.00–3.04)
1.80 (1.02–3.19)
1.72 (0.97–3.04)
2.00 (1.09–3.66)
2.13 (1.14–3.97)
2.06 (1.10–3.85)
for trend
0.09
0.07
0.10
0.06
0.04
0.05
ApoB/apoA-I
Quartile 1
29
21
1591
1.00
1.00
1.00
1.00
1.00
1.00
Quartile 2
37
28
1547
1.43 (0.88–2.34)
1.39 (0.85–2.29)
1.34 (0.81–2.21)
1.50 (0.85–2.66)
1.43 (0.80–2.55)
1.38 (0.77–2.48)
Quartile 3
40
29
1496
1.43 (0.88–2.32)
1.44 (0.87–2.37)
1.42 (0.86–2.34)
1.42 (0.80–2.51)
1.36 (0.76–2.44)
1.34 (0.74–2.41)
Quartile 4
41
35
1362
2.18 (1.34–3.58)
2.06 (1.24–3.41)
2.00 (1.21–3.31)
2.58 (1.47–4.51)
2.38 (1.34–4.23)
2.33 (1.32–4.14)
for trend
0.019
0.046
0.058
0.007
0.037
0.023
Model 1 was adjusted for age, gender, education, marriage, leisure-time physical activity, smoking, and alcohol drinking.
bModel 2 was adjusted for model 1 covariates plus type, severity, duration, and treatment of CAD, history of diabetes, history of heart failure, BMI, systolic blood pressure, glomerular filtration rate, and use of antihypertensive drugs, antidiabetic drugs, and antiplatelet drugs.
cModel 3 was adjusted for model 2 covariates plus use of cholesterol-lowering drugs.
